Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for MGC028 (ADAM9-Targeted ADC) in Advanced Solid Tumors, Cancer. The expected timing is based on the latest available company guidance and may change.
11/12/25:- MGC028, an ADAM9-targeted ADC with a topoisomerase 1 inhibitor-based payload, is in an ongoing Phase 1 dose escalation study in advanced solid tumors; timing for initial safety and efficacy data has not yet been specified. 03/09/26:- Initial Ph1 MGC028 clinical data expected in H2 2026. 05/13/26:- Ph1 dose escalation in advanced solid tumors ongoing; initial MGC028 clinical data expected in H2 2026. 08/13/26:- Ph1 dose escalation continues. Preliminary clinical results are expected in Late 2026.
Verification
Confirm timing and program details against the company announcement or filing.